Synopsis
Synopsis
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Hydrochloride, Mianserin
2. Lerivon
3. Mianserin
4. Mianserin Monohydrochloride
5. Monohydrochloride, Mianserin
6. Org Gb 94
7. Tolvon
1. 21535-47-7
2. Mianserin Hcl
3. Mianserine Hydrochloride
4. Athymil
5. Bolvidon
6. Tolvon
7. Org Gb 94
8. Mianserin (hydrochloride)
9. Lerivon
10. Tetramide
11. Mianserine Hcl
12. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
13. Mls000069681
14. 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
15. Org Gb-94 Hcl
16. Nsc-759590
17. Smr000058472
18. Org-gb 94
19. 2x03tn217s
20. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)-pyrazino(1,2-a)azepine Monohydrochloride
21. Dibenzo(c,f)pyrazino(1,2-a)azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, Monohydrochloride
22. Tolvin
23. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo(c,f)pyrazino(1,2-a)azepine Hydrochloride
24. Chebi:31843
25. Sr-01000000185
26. C18h20n2.hcl
27. Gb 94
28. Tetramide (tn)
29. Prestwick_514
30. Einecs 244-426-7
31. Mianserin Hydrochloride [usan:jan]
32. Mfcd00055072
33. (.+-.)-athymil
34. Opera_id_1505
35. (.+-.)-norval
36. Cid_68551
37. Mls001148213
38. Mls002222220
39. Schembl340474
40. Spectrum2300292
41. Unii-2x03tn217s
42. Chembl544428
43. Mianserin Hydrochloride Solution
44. Mianserin For System Suitability
45. Bdbm31005
46. Hy-b0188a
47. Dtxsid30944145
48. Hms1568c20
49. Pharmakon1600-02300292
50. Bcp09259
51. Mianserin Hydrochloride (jan/usan)
52. Mianserin Hydrochloride [mi]
53. Tox21_500744
54. Ccg-39108
55. Mianserin Hydrochloride [jan]
56. Nsc292267
57. Nsc759590
58. S1382
59. Mianserin Hydrochloride [usan]
60. Akos015902308
61. Cs-2079
62. Ks-5096
63. Lp00744
64. Mianserin Hydrochloride [mart.]
65. Nsc 759590
66. Nsc-292267
67. Mianserin Hydrochloride [who-dd]
68. Ncgc00094086-01
69. Ncgc00094086-02
70. Ncgc00094086-03
71. Ncgc00094086-04
72. Ncgc00261429-01
73. Ac-25005
74. Bm166416
75. Db-045611
76. Eu-0100744
77. M2623
78. Sw196707-3
79. Mianserin Hydrochloride [ep Monograph]
80. C74052
81. D01358
82. M 2525
83. 535m477
84. A912434
85. Sr-01000000185-2
86. Sr-01000000185-4
87. Sr-01000000185-8
88. W-111733
89. Q27114695
90. Mianserin Hydrochloride 1.0 Mg/ml In Methanol (as Free Base)
91. Mianserin Hydrochloride, Analytical Standard, For Drug Analysis
92. Mianserin Hydrochloride, European Pharmacopoeia (ep) Reference Standard
93. 1,2,3,4,10,14b-hexahydro-2-methyldi Benzo[c,f]pyrazino[1,2-a]azepine Hydrochloride
94. 1,2,3,4,10,14b-hexahydro-2-methyldibenzo[c,f]pyryzino[1,2-a]azepine Hydrochloride
95. 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepinehydrochloride
96. Mianserin For System Suitability, European Pharmacopoeia (ep) Reference Standard
97. 5-methyl-2,5-diazatetracyclo[13.4.0.0^{2,7.0^{8,13]nonadeca-1(19),8,10,12,15,17-hexaene;hydrochloride
98. 5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene;hydrochloride
99. 78644-54-9
100. Dibenzo[c,f]pyrazino[1,2-a]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-, Hydrochloride (1:1)
101. Hydron;5-methyl-2,5-diazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(19),8,10,12,15,17-hexaene;chloride
102. Mianserin Hydrochloride Solution, 1.0 Mg/ml In Methanol (as Free Base), Ampule Of 1 Ml, Certified Reference Material
Molecular Weight | 300.8 g/mol |
---|---|
Molecular Formula | C18H21ClN2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 300.1393264 g/mol |
Monoisotopic Mass | 300.1393264 g/mol |
Topological Polar Surface Area | 6.5 Ų |
Heavy Atom Count | 21 |
Formal Charge | 0 |
Complexity | 342 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Adrenergic alpha-Antagonists
Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. (See all compounds classified as Adrenergic alpha-Antagonists.)
Antidepressive Agents, Second-Generation
A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake. (See all compounds classified as Antidepressive Agents, Second-Generation.)
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Serotonin Antagonists
Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or SEROTONIN RECEPTOR AGONISTS. (See all compounds classified as Serotonin Antagonists.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Mianserin Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Mianserin Hydrochloride, including repackagers and relabelers. The FDA regulates Mianserin Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Mianserin Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Mianserin Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Mianserin Hydrochloride supplier is an individual or a company that provides Mianserin Hydrochloride active pharmaceutical ingredient (API) or Mianserin Hydrochloride finished formulations upon request. The Mianserin Hydrochloride suppliers may include Mianserin Hydrochloride API manufacturers, exporters, distributors and traders.
click here to find a list of Mianserin Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Mianserin Hydrochloride DMF (Drug Master File) is a document detailing the whole manufacturing process of Mianserin Hydrochloride active pharmaceutical ingredient (API) in detail. Different forms of Mianserin Hydrochloride DMFs exist exist since differing nations have different regulations, such as Mianserin Hydrochloride USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Mianserin Hydrochloride DMF submitted to regulatory agencies in the US is known as a USDMF. Mianserin Hydrochloride USDMF includes data on Mianserin Hydrochloride's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Mianserin Hydrochloride USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Mianserin Hydrochloride suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Mianserin Hydrochloride Drug Master File in Japan (Mianserin Hydrochloride JDMF) empowers Mianserin Hydrochloride API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Mianserin Hydrochloride JDMF during the approval evaluation for pharmaceutical products. At the time of Mianserin Hydrochloride JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Mianserin Hydrochloride suppliers with JDMF on PharmaCompass.
A Mianserin Hydrochloride CEP of the European Pharmacopoeia monograph is often referred to as a Mianserin Hydrochloride Certificate of Suitability (COS). The purpose of a Mianserin Hydrochloride CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Mianserin Hydrochloride EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Mianserin Hydrochloride to their clients by showing that a Mianserin Hydrochloride CEP has been issued for it. The manufacturer submits a Mianserin Hydrochloride CEP (COS) as part of the market authorization procedure, and it takes on the role of a Mianserin Hydrochloride CEP holder for the record. Additionally, the data presented in the Mianserin Hydrochloride CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Mianserin Hydrochloride DMF.
A Mianserin Hydrochloride CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Mianserin Hydrochloride CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Mianserin Hydrochloride suppliers with CEP (COS) on PharmaCompass.
Mianserin Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Mianserin Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Mianserin Hydrochloride GMP manufacturer or Mianserin Hydrochloride GMP API supplier for your needs.
A Mianserin Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Mianserin Hydrochloride's compliance with Mianserin Hydrochloride specifications and serves as a tool for batch-level quality control.
Mianserin Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Mianserin Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Mianserin Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Mianserin Hydrochloride EP), Mianserin Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Mianserin Hydrochloride USP).
LOOKING FOR A SUPPLIER?